Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

被引：0
|
作者：
Ji Hye Min
Ho Yun Lee
Hoyeong Lim
Myung-Ju Ahn
Keunchil Park
Man Pyo Chung
Kyung Soo Lee
机构：
[1] Samsung Medical Center,Deparment of Radiology
[2] Sungkyunkwan University School of Medicine,The Division of Hematology
[3] Samsung Medical Center,Oncology, Department of Internal Medicine
[4] Sungkyunkwan University School of Medicine,Division of Respiratory and Critical Care Medicine at the Department of Internal Medicine
[5] Samsung Medical Center,undefined
[6] Sungkyunkwan University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Tyrosine kinase inhibitors; Drug-associated interstitial lung disease; Pulmonary toxicity; Gefitinib; Erlotinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1099 / 1109
页数：10
相关论文
共 50 条
  • [21] Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
    Ohtaki, Yoichi
    Shimizu, Kimihiro
    Suzuki, Hiroyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Mitsudomi, Tetsuya
    Takao, Motoshi
    Murakawa, Tomohiro
    Ito, Hiroyuki
    Yoshimura, Kenichi
    Okada, Morihito
    Chida, Masayuki
    LUNG CANCER, 2021, 153 : 108 - 116
  • [22] Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
    Poon, Candice C.
    Kelly, John J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 1945 - 1954
  • [23] The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
    Nikolinakos, Petros
    Heymach, John V.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S131 - S134
  • [24] EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) RELATED INTERSTITIAL LUNG DISEASE IN TAIWANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Chiang, Chi-Lu
    Tsai, Chun-Ming
    Lee, Yu-Chin
    Chiu, Chao-Hua
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S592 - S592
  • [25] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [26] The Radiosensitivity of Tyrosine Kinase Driven Non-small Cell Lung Cancer
    Johung, K. L.
    Yu, J. B.
    Gettinger, S. N.
    Decker, R. H.
    Hess, J. A.
    Chiang, V. L.
    Contessa, J. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S115 - S115
  • [27] Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer
    Fukuda, Kiyoko
    Katsurada, Naoko
    Kawa, Yoshitaka
    Satouchi, Miyako
    Kaneshiro, Kazumi
    Matsumoto, Masataka
    Takamiya, Rei
    Hatakeyama, Yukihisa
    Dokuni, Ryota
    Matsumura, Kanoko
    Katsurada, Masahiro
    Nakata, Kyosuke
    Yoshimura, Sho
    Tachihara, Motoko
    HELIYON, 2023, 9 (10)
  • [28] Receptor tyrosine kinase mutations in non-small cell lung cancer
    Hayashi, H.
    Togashi, Y.
    Terashima, M.
    Sakai, K.
    Mizuuchi, H.
    Kobayashi, Y.
    Suda, K.
    Nakagawa, K.
    Nishio, K.
    Mitsudomi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S601 - S601
  • [29] Fatal interstitial lung disease associated with a series of tyrosine kinase inhibitors treatment in a non-small cell lung cancer patient: a case report
    Han, Ting
    Hu, Jiong
    Shi, Yongheng
    Wang, Liwei
    Jiao, Feng
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (05) : 3762 - 3765
  • [30] Drug-Induced Interstitial Lung Disease: A Systematic Review
    Skeoch, Sarah
    Weatherley, Nicholas
    Swift, Andrew J.
    Oldroyd, Alexander
    Johns, Christopher
    Hayton, Conal
    Giollo, Alessandro
    Wild, James M.
    Waterton, John C.
    Buch, Maya
    Linton, Kim
    Bruce, Ian N.
    Leonard, Colm
    Bianchi, Stephen
    Chaudhuri, Nazia
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (10):
12345